Further 'Slight Modifications' To Advisory Panel Process Likely
This article was originally published in The Gray Sheet
Executive Summary
FDA's device center said it will continue to assess its advisory panel process, a week after the first two meetings were held without the traditional up-or-down vote on device approvability